Allocating cancer-directed expenditures: Tensions between prevention, early detection and treatment is unnecessary

Recent Results in Cancer Research

Volumn 188, Issue , 2011, Pages 1-9

  Hillner, Bruce E ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CARBOPLATIN; CHICKENPOX VACCINE; DIAGNOSTIC AGENT; DOCETAXEL; GASTROINTESTINAL AGENT; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; HEMOSTATIC AGENT; INFLIXIMAB; NEUROLEPTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PACLITAXEL; PARICALCITOL; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RESPIRATORY TRACT AGENT; RITUXIMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; WART VIRUS VACCINE; ZOLEDRONIC ACID;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; KIDNEY CANCER; LIFE EXPECTANCY; LYMPHOMA; MEDICAL TECHNOLOGY; OVARY CANCER; PRIORITY JOURNAL; RESOURCE ALLOCATION;

EARLY DETECTION OF CANCER; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; NEOPLASMS;

EID: 79551537879     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10858-7_1     Document Type: Article

References (25)

1. Aaron HJ, Ginsburg PB (2009) Is health spending excessive? If so, what can we do about it? Health Aff 28:1260-1275
2. Bach PB (2009) Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633
3. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784-1792
4. Cutler DM Making sense of medical technology. (2006) Health Aff 25(2):w48-50
5. Dodwell D, Thorpe H, Coleman R (2009) Refining systemic therapy for early breast cancer: Difficulties with subtraction. Lancet Oncol 10:738-739
6. Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573
7. Fojo T, Grady C (2009) How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048
8. Garber AM, Tunis SR (2009) Does comparativeeffectiveness research threaten personalized medicine? N Engl J Med 360:1925-1927
9. Gavel S (2008) The oncology pipeline: Maturing, competitive and growing. oncology business review 2008;September:14-17
10. Hoffman JM, Shah ND, Vermeulen LC et al (2008) Projecting future drug expenditures - 2008. Am J Health Syst Pharm 65:234-253
11. Hoffman JM, Shah ND, Vermeulen LC et al (2009) Projecting future drug expenditures - 2009. Am J Health Syst Pharm 66:237-257
12. Hu JC, Gu X, Lipsitz SR et al (2009) Comparative effectiveness of minimally invasive vs open radical prostatectomy. Jama 302:1557-1564
13. Iglehart JK (2009) Prioritizing comparative-effectiveness research - IOM recommendations. N Engl J Med 361:325-328
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-49
15. Mandelblatt JS, Cronin KA, Bailey S et al (2009) Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms. Ann Intern Med 151:738-747
16. Meropol NJ, Schulman KA (2007) Cost of cancer care: Issues and implications. J Clin Oncol 25:180-186
17. Meropol NJ, Schrag D, Smith TJ, et al. (2009) American Society of Clinical Oncology Guidance Statement: The cost of cancer care. J Clin Oncol JCO.2009.23.1183
18. Mitchell JM (2008) Utilization trends for advanced imaging procedures: Evidence from individuals with private insurance coverage in California. Med Care 46:460-466
19. Murray CJL, Frenk J (2010) Ranking 37th - measuring the performance of the US Health Care System. N Engl J Med 362:98-99
20. NHPCO Facts and Figures: Hospice Care in America. National Hospice and Palliative Care Organization. less.http://www.nhpco.org/files/ public/Statistics-Research/NHPCO-facts-and-figures.pdfAccessed March 12, 2010
21. Peeters A, Grutters JPC, Pijls-Johannesma M et al (2010) How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010 Apr;95(1):45-53. Epub 2010 Jan 26
22. Siminoff LA, Fetting JH (1989) Effects of outcome framing on treatment decisions in the real world: Impact of framing on adjuvant breast cancer decisions. Med Dec Making 9(4):262-271
23. Smith T, Hillner B (2010) Concrete options and ideas for increasing value in oncology care: The view from one trench. Oncologist. 2010;15 Suppl 1:65-72
24. Steinbrook R (2008) Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 359: 1977-1981
25. Yabroff KR, Lamont EB, Mariotto A et al (2008) Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630-641